Stockscreener 앱 받기
4.50
9.64%
-0.48
시간 외 거래:
4.43
-0.07
-1.56%
전일 마감가:
$4.98
열려 있는:
$5
하루 거래량:
166.96K
Relative Volume:
0.86
시가총액:
$9.32M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.2942
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
-37.93%
1개월 성능:
-58.51%
6개월 성능:
-71.96%
1년 성능:
-92.24%
1일 변동 폭
$4.42
$5.0889
1주일 범위
$4.42
$7.50
52주 변동 폭
$4.42
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.50 | 10.31M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital A - GuruFocus
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
CapEx per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView — Track All Markets
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus
HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation - Nasdaq
Moleculin Biotech raises $6.5 million through warrant exercise By Investing.com - Investing.com Nigeria
Moleculin Biotech Enters Inducement Offer Agreements - TipRanks
Moleculin Biotech stock falls after warrant exercise agreement By Investing.com - Investing.com South Africa
Moleculin Biotech stock falls after warrant exercise agreement - Investing.com India
Moleculin Biotech raises $6.5 million through warrant exercise - Investing.com
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - The Manila Times
Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants for Gross Proceeds of Approximately $6.5 Million - Quiver Quantitative
Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan
Moleculin Biotech (MBRX) Stock: Faces Market Drop Despite Positive MIRACLE Trial Enrollment Progress - parameter.io
Moleculin Biotech (MBRX) Approaches Key Enrollment Milestone in Leukemia Study - GuruFocus
Moleculin Biotech Updates on MIRACLE Study Progress - TipRanks
Moleculin stock rises as AML trial enrollment reaches 78% By Investing.com - Investing.com Nigeria
Moleculin Biotech, Inc. Updates on MIRACLE Phase 2B/3 AML Trial Progress - TradingView — Track All Markets
Moleculin stock rises as AML trial enrollment reaches 78% - Investing.com
Moleculin reports 78% enrollment in AML treatment trial - Investing.com
Moleculin reports 78% enrollment in AML treatment trial By Investing.com - Investing.com South Africa
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal 'MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - The Manila Times
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - Sahm
Moleculin (Nasdaq: MBRX) Tracks Toward 45-Patient MIRACLE AML Readout in Q1 2026 - Stock Titan
The MIRACLE Test: Trial Progress And Market Moves Put Moleculin In Focus - RTTNews
Moleculin enters research agreement for brain cancer treatment By Investing.com - Investing.com Australia
After tax other income/expense of Moleculin Biotech, Inc. – BER:MOL0 - TradingView — Track All Markets
Moleculin Biotech Partners with CIC biomaGUNE for Research - TipRanks
Moleculin Biotech (MBRX) Partners with CIC biomaGUNE for Brain C - GuruFocus
Moleculin enters research agreement for brain cancer treatment - Investing.com
Moleculin Announces New Annamycin Collaboration in Brain Tumors - The Manila Times
Moleculin Biotech, Inc. Partners with CIC biomaGUNE for Preclinical Research on Annamycin as a Treatment for Glioblastoma Multiforme - Quiver Quantitative
Moleculin announces new Annamycin collaboration in brain tumors - marketscreener.com
Moleculin (Nasdaq: MBRX) joins CIC biomaGUNE to study Annamycin in GBM models - Stock Titan
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (MBRX) Price Target Increased by 2,399.99% to 170.00 - Nasdaq
Net debt of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
After tax other income/expense of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView
Basic earnings per share (basic EPS) of Moleculin Biotech, Inc. – LS:A41SET - TradingView
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Geopolitics Watch: Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Reactions & Fast Momentum Entry Tips - BỘ NỘI VỤ
Moleculin Biotech, Inc.: Revenue and Earnings Analysts Forecasts Revisions | MOL0 | US60855D4088 - marketscreener.com
Moleculin Biotech, Inc.: Financial Data Forecasts Estimates and Expectations | MOL0 | US60855D4088 - marketscreener.com
Moleculin Biotech, Inc.: Dividend historical data and projections - marketscreener.com
Moleculin Biotech, Inc.: Target Price Consensus and Analysts Recommendations | MOL0 | US60855D4088 - marketscreener.com
How supply shortages influence Moleculin Biotech Inc. (MOL) stockPortfolio Profit Report & Precise Swing Trade Alerts - Newser
Moleculin Biotech Inc (FRA:MOL0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Moleculin Biotech Inc (FRA:MOL0) Stock Earnings Transcripts - GuruFocus
Why Moleculin Biotech Inc. stock attracts global investors2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Enterprise value to EBITDA ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):